Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2019

View Archived Issues

Genetic ablation of CD33 in human stem/progenitor cells enables immunotherapy against leukemia

When prey becomes predator

Scorpion venom used to fight S. aureus and M. tuberculosis

BeiGene updates on clinical results with zanubrutinib

Colorectal tumors that metastasize do it early

TNF and tinnitus

Acer Therapeutics receives complete response letter from FDA for use of Edsivo

Positive results presented from phase IIb trial of BPX-04 for papulopustular rosacea

Imbrium plans phase II study of IMB-115 for insomnia associated with alcohol cessation

FDA clears IND for the PROTAC protein degrader ARV-471

phiMR-003, a promising new therapeutic phage for MRSA infection

Positive topline phase I data support continued development of RDN-929

Statistical significance not achieved for the primary or secondary endpoints of the SOLACE study

EC grants marketing authorization for Doptelet for severe thrombocytopenia in adults with CLD

Researchers unveil LRP6 gene to be associated with familial hypercholesterolemia

Bionomics patents nicotinic alpha7 receptor negative allosteric modulators

Study gives insights into Parkinson's beyond dopamine

New lactam derivatives acting as H3 receptor ligands with potential for the treatment of pain

Researchers identify new compounds for respiratory diseases

Cadila Healthcare discloses IRAK-4 inhibitors

AstraZeneca synthesizes new RAS mutant inhibitors

Vivace Therapeutics presents YAP1/TEAD interaction inhibitors

FDA issues complete response letter for Ryaltris NDA

Phase IIb study of SPI-1005 in Meniere's disease meets endpoints

Promising first data for [212Pb]DOTAMTATE in patients with SSTR-positive neuroendocrine tumors

FDA allows Translate Bio to begin SAD phase I/II study of MRT-5201 for OTC deficiency

Faron reports interim data from phase II INFORAAA study of Traumakine

NantKwest cleared to begin first-in-human study with PD-L1 t-haNK cell therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 17, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...